AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Why Did SES AI Stock Plunge 13.87%? Earnings Miss 22.22%
Generated by AI AgentAinvest Pre-Market Radar
Tuesday, Aug 5, 2025 4:13 am ET1min read
Aime SummaryOn August 5, 2025, SES AI's stock price plummeted by 13.87% in pre-market trading, marking a significant decline for the company.
SES AI Corporation reported its second-quarter earnings for 2025, revealing a revenue of $3.5 million, which fell short of the expected $4.5 million, resulting in a 22.22% miss. This shortfall in revenue estimates was a key factor contributing to the stock's decline. The company's actual revenues of $3.5 million for the quarter were significantly lower than the anticipated $4.5 million, highlighting the challenges faced by the company in meeting market expectations.
Despite the financial setbacks,
has maintained a lean and capital-light operational structure, with no debt and a robust 74% gross margin driven by strong service performance. The company's focus on cutting-edge battery solutions has attracted attention and revenue, although it remains an early-stage company. Additionally, Corporation regained compliance with NYSE listing criteria by August 2025, after being notified of non-compliance in March 2025. This regulatory compliance is a positive development for the company, but it may not be enough to offset the impact of the revenue miss on investor sentiment.
Ainvest Pre-Market Radar
Get the scoop on pre-market movers and shakers in the US stock market.
Latest Articles
Getty Images (NYSE:GETY) surges 5.51% on renewed investor confidence
Jan.02 2026
Olaplex Holdings (NASDAQ: OLPX) shares plunged 7.59% on mixed analyst outlooks and shifting institutional positioning.
Jan.02 2026
The Real Brokerage shares surge 7.04% on Jan. 2 2026 driven by regulatory tailwinds and restructuring optimism
Jan.02 2026
Vanda Pharmaceuticals shares surged 25.46% on partnership and FDA Breakthrough Therapy Designation.
Jan.02 2026
Vanda Pharmaceuticals shares surge 25.46% on partnership and FDA breakthrough designation
Jan.02 2026
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments

No comments yet